Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.57 |
| ▸ | CTSC | P53634 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413310 | 1.00 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL3385081 | 0.98 | MMP8 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL27492563 | 0.98 | MMP8 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21781783 | 0.92 | MMP8 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21137540 | 0.92 | MMP8 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL15623830 | 0.92 | OPRK1 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8817411 | 0.91 | ALDH1A1 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8817408 | 0.91 | ALDH1A1 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8131629 | 0.91 | ALDH1A1 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21768262 | 0.88 | PTPN1 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002028829-A2 | PEPTIDE DEFORMYLASE INHIBITORS | QUESTCOR PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | claimed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0689538-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1998-08-12 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5652262-A | Hydroxamic acid derivatives as metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICAL, LTD. (GB) | 1997-07-29 | — | — | US | disclosed |
| EP-0689538-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021625-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-09-29 | — | — | WO | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | ALPI 4834/4885PKM 2445/4885PTGS1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.